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THE EPITHELIUM LINING the respiratory tract in humans is composed of ciliated, nonciliated, and basal cells. These are the first cells to be exposed to an inhaled allergen (17) . Damage to the epithelial cell lining results in cilial dysfunction, loss of cellular integrity, and penetration of allergens into the airways. Loss of epithelial integrity is a major feature of asthma pathogenesis and is thought to be an important contributor to the development of airway hyperresponsiveness (8) . Resident mast cells in the pulmonary interstitium are important facilitators in the epithelial cell response to external injury. They secrete a host of mediators from the preformed granules including tryptase, chymase, and carboxypeptidase, which affect tissue remodeling and inflammatory cell recruitment (8, 25) . In addition, mast cells also contain histamine, a vasoactive amine with potent effects on vascular permeability. Platshon and Kaliner (34) have concluded that histamine stimulation of human lung tissue leads to increased synthesis of PGF 2␣ and cGMP in response to H-1 receptor stimulation and of cAMP through H-2 receptor stimulation. The rapid degranulation and release of tryptase following mast cell exposure to allergens provides a signal for activation of phospholipases, initiation of vascular change, and mobilization and recruitment of effector inflammatory cells (8, 17, 25, 34) .
Previous studies from our laboratory (35, 36) have demonstrated that tryptase stimulation of endothelial cells can lead to activation of a calcium-independent phospholipase A 2 (iPLA 2 ), which hydrolyzes membrane phospholipids resulting in the stoichiometric production of a fatty acid, including arachidonic acid, and a lysophospholipid. In airway epithelial cells, arachidonic acid is further catabolized to eicosanoids, most typically PGE 2 . PGE 2 acts on various E-prostanoid (EP) receptors and has been implicated in modulating human airway smooth muscle function. Activation of EP1 and EP3 receptors mediates airway smooth muscle contraction, whereas stimulation of EP2 receptors produces muscle relaxation (20) .
The iPLA 2 family of enzymes is made up of at least seven members (37) . The first mammalian iPLA 2 described was iPLA 2 ␤ (group VIA PLA 2 ; Ref. 14) . In 2000, two independent laboratories identified a novel iPLA 2 , iPLA 2 ␥ (group VIB PLA 2 ), which is constitutively membrane bound and possesses a COOH-terminal serine-lysine-leucine (SKL) peroxisomal targeting sequence (26, 28, 42) . Multiple forms of iPLA 2 ␥ exist, and the expression of iPLA 2 ␥ is subject to rigorous control at many levels although the precise mechanisms for this are still not completely understood.
iPLA 2 ␥ protein expression has been confirmed in the mouse (28) and rat heart (27) , rat liver (47) , and human platelets (6) by immunoblot analysis. Overall, iPLA 2 ␥ expression appears to be widespread, but commercially available tools for the study of iPLA 2 ␥ (e.g., antibody, specific inhibitors, validated small interfering RNA, etc.) are only now becoming available. Both iPLA 2 ␤ and iPLA 2 ␥ are sensitive to inhibition by bromoenol lactone (BEL) at low micromolar concentrations (26) . However, other pharmacological PLA 2 inhibitors, such as arachidonyl trifluoromethylketone (AACOCF 3 ) and methyl arachidonyl fluorophosphonate (MAFP), which inhibit cytosolic iPLA 2 ␤ at low micromolar concentrations (1, 21), do not inhibit microsomal iPLA 2 ␥ (10). Furthermore, Jenkins et al. (18) demonstrated that separation of racemic BEL into the R-and S-enantiomers provides a mechanism to discriminate between iPLA 2 ␥ and iPLA 2 ␤ activity (i.e., iPLA 2 ␥ is ϳ10-fold more sensitive to R-BEL than to S-BEL, and iPLA 2 ␤ is 10-fold more sensitive to S-BEL than to R-BEL; Ref. 18 ).
This study examines the effect of tryptase stimulation on human small airway epithelial cell (HSAEC) PLA 2 activity and the subsequent production of arachidonic acid, PGE 2 , and platelet activating-factor (PAF) and discusses the implications of these findings in small airway inflammation.
MATERIALS AND METHODS
HSAEC were obtained from Lonza Walkersville (Walkersville, MD). BEL, CAY10404, and SC-560 were obtained from Cayman Chemicals (Ann Arbor, MI). Recombinant human skin ␤-tryptase was obtained from Promega (Madison, WI). PX-18 was a gift from Richard Berney Associates (Bethesda, MD). CV3988 was purchased from Sigma-Aldrich (St. Louis, MO). All other reagents were purchased from Sigma-Aldrich.
Culture of epithelial cells. HSAEC were grown to confluence in small airway basal medium (SABM; Lonza Walkersville) and incubated at 37°C with an atmosphere of 95% O 2-5% CO2. Cells were passaged using subculture pack (Lonza Walkersville) in a 1:3 ratio. Cells from passages 3-4 were used for experiments.
PLA2 activity. Cells were grown to confluence in 100-mm culture dishes. At the end of each incubation period, media was removed and immediately replaced with ice-cold buffer containing, in mmol/l, 250 sucrose, 10 KCl, 10 imidazole, 5 EDTA, and 2 dithiothreitol, with 10% glycerol (pH 7.8). The cells were removed from the tissue culture plate by scraping, and the suspension was sonicated on ice for six bursts of 10 s. For separating the cells into membrane and cytosolic fractions, the sonicate was centrifuged at 14,000 g for 10 min. The supernatant was centrifuged at 100,000 g for 60 min to separate the membrane fraction (pellet) from the cytosolic fraction (supernatant ) phosphatidylcholine (specific activity ϳ150 dpm/pmol) in assay buffer containing 10 mM Tris, 10% glycerol, 4 mM EGTA, pH 7.0, at 37°C for 5 min in a total volume of 200 l. For determining the sensitivity of membrane activity to R-BEL or S-BEL, the appropriate inhibitor was added to the isolated membrane fraction in the assay buffer for 10 min before the initiation of the activity assay. Reactions were initiated by adding the radiolabeled phospholipid substrate as a concentrated stock solution in ethanol. Reactions were terminated by the addition of 100 l of butanol. The radiolabeled fatty acid released in the above reaction was isolated by application of 25 l of the butanol phase to channeled Silica Gel G plates and then developed in petroleum ether-diethyl ether-acetic acid (70 10 glucose, and 0.36% BSA and incubated at 37°C for 15 min before experimental conditions. At the end of the stimulation period, the surrounding medium was transferred to a scintillation vial, the remaining cells were lysed in 10% SDS, and the lysate was then transferred to a separate vial. Radioactivity in the medium and cells was quantified by liquid scintillation spectrometry. Arachidonic acid mobilized from cellular phospholipids was expressed as the percentage of total incorporated radioactivity.
PGE2 release. HSAEC were grown to confluence in 16-mm tissue culture dishes. Cells were washed twice with HBSS containing, in mmol/l, 135 NaCl, 0.8 MgSO4, 10 HEPES (pH 7.6), 1.2 CaCl2, 5.4 KCl, 0.4 KH2PO4, 0.3 Na2HPO4, and 6.6 glucose. After washing, 0.5 ml of HBSS with 0.36% BSA was added to each culture well. HSAEC were then stimulated with the appropriate tryptase concentrations. The surrounding buffer was removed from the HSAEC after selected time intervals, and PGE2 release was measured immediately using an immunoassay kit (R&D Systems, Minneapolis, MN). The protein content for the HSAEC confluent monolayers was determined in three representative cell culture wells and was assumed to be constant between wells for each experiment.
PAF assay. HSAEC grown in 34-mm culture dishes (Corning) were washed twice with HBSS. Cells were incubated with 10 Ci of [ 3 H]acetic acid per well for 20 min. After stimulation with tryptase, lipids were extracted from the cells using the method of Bligh and Dyer. The chloroform layer was concentrated by evaporation under nitrogen, resuspended in 9:1 CHCl3-CH3OH, applied to a silica gel 60 TLC plate, and developed in chloroform-methanol-acetic acid-water (50:25:8:4 vol/vol/vol/vol). The region corresponding to [ 3 H]PAF was scraped, and radioactivity was quantified by liquid scintillation spectrometry. Loss of PAF during extraction and chromatography was corrected by adding a known amount of [ 14 C]PAF as an internal standard.
PAF-acetylhydrolase assay. HSAEC grown to confluence were incubated with BEL for 10 min and then removed from the tissue culture plate in 1.2 mM Ca 2ϩ HEPES buffer and sonicated on ice. Cellular protein (25 g) was incubated with 0.1 mM [acetyl-
3 H]PAF (10 mCi/mmol) for 30 min at 37°C. The reaction was stopped by the addition of acetic acid and sodium acetate. Released [ 3 H]acetic acid was isolated by passing the reaction mixture through a C18 silica gel column (J. T. Baker, Phillipsburg, NJ), and eluted radioactivity was measured using a liquid scintillation counter.
Neutrophil isolation procedure. Adult peripheral blood was collected (approved by Saint Louis University School of Medicine Institutional Review Board no. 12369) in vials containing 3.8% sodium citrate layered over Polymorphprep (Axis-Shield PoC AS, Oslo, Norway) and centrifuged at 500 g for 30 min. The top band at the sample/medium interface consisting of mononuclear cells and the lower band of polymorphonuclear cells were removed and washed with HBSS. Supernatant was discarded, and the cell pellet resuspended with 3 ml of 0.2% NaCl and incubated for 3 min at room temperature to lyse the red cells. Cells were again resuspended in HBSS and centrifuged at 175 g for 10 min at 4°C. Supernatant was removed, and cells resuspended in 5 ml of ice-cold HBSS. An aliquot was taken for a cell count using a hemacytometer.
Neutrophil adherence assay. Neutrophils were resuspended in HBSS at 1 ϫ 10 6 cells per milliliter. HSAEC were grown to confluence on a 12-well plate and washed with HBSS, and respective stimulants/inhibitors were added. CV3988 was added directly to the neutrophils when used. Five hundred microliters of neutrophils in suspension were added to each of the wells and incubated for 10 min at room temperature. Media and unbound neutrophils were removed and discarded. Plates were washed twice with Dulbecco's PBS. One milliliter of 0.2% Triton X-100 was added to each well to lyse adherent neutrophils and HSAEC. Cell lysates were scraped from the plate and transferred to an Eppendorf tube. A 500-l aliquot of neutrophil suspension was added to 500 l of 0.2% Triton X-100 and used as the theoretical maximal binding sample. Samples were sonicated (550 Sonic Dismembrator; Fisher Scientific, Pittsburgh, PA) for 10 s. To measure neutrophil peroxidase activity, 400 l of cell lysate was transferred to a glass tube, 1 ml of PBS, 1.2 ml of HBSS ϩ BSA, 200 l of 3,3Ј-dimethoxybenzidine, and 200 l of 0.05% H2O2 were added, and the mix was incubated for 15 min at room temperature. Two hundred microliters of 1% sodium azide (NaN3) was added to stop the reaction. The absorbance was then measured using a 4050 UV-Visible Spectrophotometer (Biochrom, Cambridge, England) at 450 nm.
Statistical analysis. Data were analyzed using the Student's t-test. P values of Ͻ0.05 were considered statistically significant; P values of Ͻ0.01 were considered highly statistically significant. ANOVA was used for comparison between multiple groups. (Fig. 1, open circles) . However, no significant increase in iPLA 2 activity was observed in tryptase-stimulated HSAEC when activity was measured using (16:0, [
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Effect of tryptase on
3 H]18:1) phosphatidylcholine substrate ( Fig. 1, closed  squares) . These data are consistent with our (35) previous finding in endothelial cells from other vascular beds and suggest that tryptase stimulates a plasmalogen-selective iPLA 2 . The tryptase-stimulated increase in iPLA 2 activity was completely inhibited by pretreating the cells with the iPLA 2 -selective inhibitor BEL (2 M, 10 min; Fig. 2, closed circles) but not by the secretory PLA 2 (sPLA 2 ) inhibitor PX-18 (2 M, 10 min; Fig. 2, X) . These data support our hypothesis that iPLA 2 activity is increased in tryptase-stimulated HSAEC.
We further examined the specific iPLA 2 isoform responsible for the increased activity measured in tryptase-stimulated HSAEC. We stimulated HSAEC with tryptase and then isolated the membrane and cytosolic subcellular fractions. iPLA 2 activity was increased in the membrane fraction of tryptasestimulated HSAEC, but cytosolic iPLA 2 activity was not significantly altered (data not shown). Subsequently, the membrane fraction was incubated with increasing concentrations of R-BEL (selectively inhibits iPLA 2 ␥) or S-BEL (selectively inhibits iPLA 2 ␤) for 10 min before the assay of iPLA 2 activity. We found that iPLA 2 activity was significantly inhibited by pretreatment with concentrations of R-BEL greater than 1 M Values represent means Ϯ SE for separate measurements from 4 different cell isolations. PLA2 activity was measured in membrane and cytosolic subcellular fractions from human small airway epithelial cells (HSAEC) using plasmenylcholine or phosphatidylcholine substrates in the absence (4 mM EGTA) or presence ( but was not inhibited by S-BEL until concentrations greater than 5 M were used (Fig. 3) . These data indicate that iPLA 2 ␥ is the major isoform present in HSAEC.
Effect of tryptase on arachidonic acid release from HSAEC. Tryptase stimulation results in a fourfold increase in arachidonic acid release by 10 min compared with unstimulated cells (Fig. 4) . Pretreatment with BEL (2 M, 10 min) before tryptase stimulation completely inhibited tryptase-induced iPLA 2 activation (Fig. 2) and arachidonic acid release (Fig. 4) . Pretreatment of HSAEC with PX-18 (2 M, 10 min) did not inhibit iPLA 2 activity (Fig. 2) but inhibited tryptase-stimulated arachidonic acid release by ϳ50% (Fig. 4) . This indicates that arachidonic acid release in tryptase-stimulated HSAEC is dependent on activation of iPLA 2 but that sPLA 2 is also involved in tryptase-stimulated arachidonic acid release.
Effect of tryptase on PGE 2 release in the presence of PLA 2 inhibitors. We stimulated HSAEC with tryptase and measured PGE 2 release in the presence and absence of PLA 2 inhibitors. Tryptase stimulation of HSAEC resulted in a significant increase in PGE 2 release after 2 min (Fig. 5) . Pretreatment with BEL (2 M, 10 min) before tryptase stimulation completely inhibited the PGE 2 release. Pretreatment with PX-18 (2 M, 10 min) inhibited the tryptase-induced PGE 2 release by ϳ70% in these cells (Fig. 5) .
Effect of tryptase on PGE 2 release in the presence of cyclooxygenase inhibitors. Arachidonic acid is metabolized by cyclooxygenase (COX)-1 and COX-2 to generate PGE 2 in epithelial cells. Pretreatment with SC-560 (15 nM, 10 min, COX-1-selective inhibitor) or aspirin (1.5 nM, 10 min, COX-1 and COX-2 inhibitor) completely inhibited tryptase-stimulated PGE 2 release from HSAEC (Fig. 6) . However, pretreatment of cells with CAY10404 (1 nM, 10 min, a COX-2-selective inhibitor) had no effect. These data indicate that in the immediate phase of tryptase-stimulated PGE 2 production it is the constitutive COX-1 isoform that is responsible for metabolizing iPLA 2 -catalyzed arachidonic acid release to generate PGE 2 .
Effect of tryptase on PAF production. The lysophospholipid generated as a consequence of removal of sn-2 fatty acid from the phospholipid by iPLA 2 is rapidly acetylated to PAF. PAF is a potent proinflammatory lipid metabolite that can result in disruption of the airway epithelial defense barrier. Tryptase stimulation of HSAEC caused an increase in PAF production that was observed until 30 min. This effect was attenuated by pretreating the cells with BEL (Fig. 7) indicating that tryptaseinduced PAF production in HSAEC is at least in part due to iPLA 2 activation. Treatment of HSAEC with concentrations of Effect of tryptase on neutrophil adherence. Previous studies from our laboratory have demonstrated significant increases in neutrophil adherence to tryptase-stimulated coronary artery endothelial cells. We examined whether tryptase stimulation would have a similar effect on the adherence of neutrophils to the HSAEC monolayer. Tryptase stimulation (20 ng/ml, 10 min) led to a significant increase in neutrophil adherence (Fig. 8) . We also saw that pretreatment of neutrophils with a PAF receptor antagonist, CV3988, reduced the percentage of adherent neutrophils by 80% (from 14.77% Ϯ 0.27% to 3.25% Ϯ 0.25%, n ϭ 4) demonstrating the importance of PAF-PAF receptor interactions in the adherence of these cells.
DISCUSSION
Activation of mast cells can release several mediators from their granules that are responsible for a variety of inflammatory allergic disorders such as allergic rhinitis, asthma, dermatitis, and anaphylactic responses. In the lung, mast cells are found widely distributed in pleura, peribronchial regions, alveolar septa adjacent to nerves and blood vessels, upper and lower respiratory epithelium, and within the bronchial lumen (8) . Tryptase released from mast cell granules has widespread effects on cellular proteins that can contribute to the pathogenesis of pulmonary inflammation in large and small airways (41) . Tryptase degrades vasoactive intestinal polypeptide, an endogenous bronchodilator, generates bronchoconstrictor kinins, and activates prekallikrein (9) . It also increases airway smooth muscle responsiveness to histamine in vitro and airway hyper responsiveness in vivo.
Airway inflammation in asthma is widely considered to be due to changes in the large airways. However, there is a significant patient population that does not respond to currently available antiasthmatic therapeutic regimens. In such cases, it is believed that the small airway (Ͻ2 mm in diameter) could be responsible for the residual inflammation. However, there are technical difficulties associated with evaluation of distal lung tissue. Only a small number of studies, using tissue obtained at the time of tumor resection or alveolar tissue from transbronchial biopsies, have evaluated distal lung inflammatory cell distribution and function (31, 38, 40) .
Small airways consist of the respiratory bronchiole and terminal bronchioles that are devoid of cartilage and mucous secreting glands (12) . Pathological changes in the small airways may proceed long before clinical symptoms of pulmonary inflammation become apparent. A hallmark of airway inflammation is widespread damage to the epithelium. There is infiltration by neutrophils and activated eosinophils (23) . Epi- thelial sloughing occurs during exacerbation of bronchial asthma and is due to a possible defect in adherence to the basement membrane (5) . The degree of airway hyperresponsiveness has been postulated to correlate with the loss of airway epithelial cells (45) .
The airway epithelium can serve as both a target and effector cell in propagating the inflammatory response. On encountering allergens, the airway epithelium reacts by increasing mucus secretion, ciliary beat frequency, and changes in the ion transport/barrier function. The inflammatory metabolites released by the epithelium can act in an autocrine or paracrine fashion to exert widespread effects. Previous studies have demonstrated that airway epithelium can release IFN-␥ and TNF-␣. These in turn can lead to production of several secondary mediators such as prostanoids (PGE 2 ), nonprostanoid mediators including epithelium derived relaxant/inhibitory factor, reactive oxygen species, and nitric oxide. PGE 2 can have both pro-and anti-inflammatory effects. Inhaled PGE 2 abolishes exercise-induced bronchoconstriction (29) . It also inhibits bronchial hyperresponsiveness to inhaled allergen and attenuates antigen-induced eosinophilic inflammation (11, 33) . Since PGE 2 is a potent vasodilator, it potentiates the edema induced by other mediators (46) . In addition, it reinforces the T helper type 2 (T H 2) responses by increasing T cell polarization and release of IL-10 while inhibiting the release of IL-12 (a T H 1-polarizing cytokine) (13) .
To the best of our knowledge, this is the first study that demonstrates that mast cell tryptase can activate membraneassociated iPLA 2 ␥ in small airway epithelial cells resulting in arachidonic acid release, which is metabolized by COX-1 to generate PGE 2 . Pretreating the cells with BEL led to complete inhibition of these responses, whereas PX-18 led to partial inhibition of arachidonic acid release and PGE 2 generation. This suggests that iPLA 2 is required for the production of arachidonic acid in the immediate response to tryptase in airway epithelial cells but that sPLA 2 may also be involved to a lesser degree.
There are three main classes of PLA 2 that coexist in mammalian cells, secretory, cytosolic, and calcium-independent PLA 2 . They are activated in a temporal sequence and exert their effect over varying lengths of time depending on the stimulus and cell type (30) . The cyclooxygenases convert arachidonic acid to an intermediate precursor PGH 2 . The release of arachidonic acid and formation of PGH 2 is the crucial rate-limiting step for prostaglandin synthesis. In the early phase of prostaglandin biosynthetic response, increased arachidonic acid production by iPLA 2 activation is followed by oxidation by constitutive COX-1 and prostaglandin biosynthesis (32) . Several published studies have described a possible role for iPLA 2 in the generation of eicosanoids. IgG receptors (FcεR) have been demonstrated to functionally couple to iPLA 2 ␤ for the release of arachidonic acid and the production of leukotriene B 4 and PGE 2 (43) . Murakami et al. (32) transfected various PLA 2 and COX enzymes into human embryonic kidney cells and observed that ionophore-induced immediate PGE 2 generation was linked to iPLA 2 ␤ and COX-1 activity. They suggested that iPLA 2 releases arachidonic acid in closer proximity to COX-1 than COX-2 and that iPLA 2 -derived arachidonic acid is somehow inaccessible to COX-2 (35). We report that immediate release of PGE 2 from tryptase-stimulated HSAEC is dependant on activation of membrane-associated iPLA 2 ␥ and subsequent metabolism of arachidonic acid by COX-1, further supporting this hypothesis.
Although intracellular PLA 2 isoforms may be directly coupled to COX in the cell for eicosanoid production, several studies suggest that immediate eicosanoid production involves cytosolic PLA 2 (cPLA 2 ) and sPLA 2 with cPLA 2 being the activator of the response but sPLA 2 providing the bulk of arachidonic acid (22) . Since tryptase-stimulated PGE 2 production in HSAEC was significantly inhibited by pretreatment with BEL and partly by PX-18, it is possible that a similar interaction between iPLA 2 and sPLA 2 is involved in arachidonic acid release. Cross talk between cPLA 2 and sPLA 2 has been previously demonstrated in P388D1 macrophages in which intracellular arachidonic acid release by cPLA 2 regulates the accessibility of sPLA 2 to its substrate in the membrane (3). A similar mechanism, at least in part, may exist between iPLA 2 and sPLA 2 in HSAEC since PX-18 inhibits tryptasestimulated arachidonic acid release and PGE 2 production but does not inhibit iPLA 2 activity.
In our studies, we also saw increased adherence of neutrophils to tryptase-stimulated HSAEC mediated by PAF. Holtzman et al. (16) have previously demonstrated PAF production by airway epithelial cells. PAF activates leukocytes and platelets via specific cell surface receptors, induces leukocyte chemotaxis, and stimulates preferential migration of eosinophils into the airway (2) . It can also induce airway smooth muscle contraction and hyperreactivity in healthy subjects (19) . Airway epithelial cells express several leukocyte adhesion molecules, and the receptors for these ligands are regulated by PAF (24, 44) .
Infiltration and adherence of neutrophils occurs during asthma and chronic bronchitis and is also a hallmark of cystic fibrosis (39) . Tryptase is known to have mitogenic effect on airway smooth muscles. In conjunction with increased neutrophil adherence, it may set up a cycle of inflammation that can induce airway remodeling and compromise lung function (7) . In light of the close proximity of HSAEC and the interstitial mast cells, the effects of tryptase seen in the above-mentioned studies can be an important pathway in propagating small airway inflammation.
The epithelium is usually regarded as a target for inflammatory mediators, but this study demonstrates that it is capable of initiating and sustaining an inflammatory response. Once targeted, the epithelium sets a cascade of inflammatory events, which can be responsible for activation of inflammatory cells, stimulation of smooth muscle, and fibroblast proliferation. Molecular mechanisms that regulate COX and lipoxygenase production in airway epithelium provide an important therapeutic target. In asthma, PLA 2 activation triggered by mast cell tryptase may contribute to the propagation of inflammation via the production of several membrane phospholipid-derived metabolites. Thus the development of a specific PLA 2 inhibitor has the potential to be a valuable therapeutic tool for treating early airway inflammation that contributes further to the pathogenesis of asthma.
